MGAH22 (margetuximab): HER2+ Tumors

Phase 2 clinical study in patients with HER2 positive solid tumors.
Learn more: MGAH22
Learn more: ClinicalTrials.gov

Platform Fact Sheets

Fc Optimization Platform (.PDF, 231.26 Kb)

Dual-Affinity Re-Targeting (DART) Platform Overview (.PDF, 1.03 Mb)

Cancer Stem Cell Platform Overview, (.PDF, 2.03 Mb)

Corporate Fact Sheet, (.PDF, 1.39 Mb)

MacroGenics Logo (vector) (.EPS, 996.84 Kb)

MacroGenics Logo (bitmap), (.JPG, 135.84 Kb)